NeoGenomics, Inc. (NASDAQ:NEO) Receives Consensus Rating of “Moderate Buy” from Brokerages

NeoGenomics, Inc. (NASDAQ:NEO) has received a consensus rating of “Moderate Buy” from the ten research firms that are currently covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $19.50.

NEO has been the subject of several analyst reports. William Blair reaffirmed an “outperform” rating on shares of NeoGenomics in a research report on Wednesday, February 21st. Needham & Company LLC lifted their price objective on NeoGenomics from $21.00 to $24.00 and gave the stock a “buy” rating in a research report on Wednesday, February 21st. BTIG Research lowered their price objective on NeoGenomics from $25.00 to $21.00 and set a “buy” rating for the company in a research report on Friday, December 29th. The Goldman Sachs Group lifted their price objective on NeoGenomics from $17.00 to $19.00 and gave the stock a “buy” rating in a research report on Thursday, February 22nd. Finally, TD Cowen lowered their price objective on NeoGenomics from $22.00 to $19.00 and set an “outperform” rating for the company in a research report on Friday, December 29th.

NeoGenomics Stock Up 0.7 %

Shares of NASDAQ:NEO opened at $13.77 on Friday. The firm has a market cap of $1.76 billion, a P/E ratio of -19.67 and a beta of 1.10. The company has a quick ratio of 5.95, a current ratio of 6.20 and a debt-to-equity ratio of 0.57. NeoGenomics has a 12-month low of $11.03 and a 12-month high of $21.22. The business has a fifty day simple moving average of $15.13 and a 200 day simple moving average of $15.82.

NeoGenomics (NASDAQ:NEO) last announced its earnings results on Tuesday, February 20th. The medical research company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.05. The business had revenue of $155.55 million during the quarter, compared to analyst estimates of $152.90 million. NeoGenomics had a negative return on equity of 4.13% and a negative net margin of 14.87%. Analysts predict that NeoGenomics will post -0.2 earnings per share for the current year.

Insider Activity

In other news, General Counsel Alicia C. Olivo sold 2,587 shares of the firm’s stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $14.96, for a total value of $38,701.52. Following the completion of the sale, the general counsel now directly owns 34,866 shares in the company, valued at approximately $521,595.36. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 1.30% of the stock is currently owned by company insiders.

Institutional Trading of NeoGenomics

Large investors have recently made changes to their positions in the company. Millennium Management LLC boosted its stake in NeoGenomics by 293.9% during the 4th quarter. Millennium Management LLC now owns 2,657,477 shares of the medical research company’s stock valued at $24,555,000 after purchasing an additional 1,982,840 shares during the last quarter. Brown Advisory Inc. boosted its stake in NeoGenomics by 25.0% during the 3rd quarter. Brown Advisory Inc. now owns 8,246,202 shares of the medical research company’s stock valued at $101,428,000 after purchasing an additional 1,651,717 shares during the last quarter. Norges Bank acquired a new position in NeoGenomics during the 4th quarter valued at about $13,090,000. Dimensional Fund Advisors LP boosted its stake in NeoGenomics by 50.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,692,607 shares of the medical research company’s stock valued at $46,880,000 after purchasing an additional 902,024 shares during the last quarter. Finally, First Light Asset Management LLC boosted its stake in NeoGenomics by 29.6% during the 4th quarter. First Light Asset Management LLC now owns 3,926,756 shares of the medical research company’s stock valued at $63,535,000 after purchasing an additional 897,843 shares during the last quarter. 98.50% of the stock is currently owned by institutional investors and hedge funds.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.